The FDA granted Fast Track designation to HTX-001, an investigational lncRNA-targeting antisense therapy for nonobstructive hypertrophic cardiomyopathy.
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results